JHVEPhoto
- Cipla, one of India’s largest pharmaceutical companies, is open to partnering with Eli Lilly (NYSE:LLY) to market Mounjaro and Zepbound, respectively indicated for diabetes and weight loss, in the country.
- “Absolutely and always open…we value our partnership with Lilly tremendously and I think the two companies are culturally aligned,” Cipla Global CEO Umang Vohra told Reuters.
- Mounjaro and Zepbound, which both contain tirzepatide, are dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists. They have already become major revenue drivers for Lilly and are so popular, there are product shortages in the U.S.
- Cipla is already partnered with Lilly (LLY) to sell the American drugmaker’s diabetes meds in India.
- In February, Lilly told Reuters that it expects to launch Mounjaro in India as soon as 2025.
Source link
